Document Detail


Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication.
MedLine Citation:
PMID:  20546237     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
PURPOSE: The purpose of this study was to investigate the tolerability and intraocular pressure (IOP) reducing effect of the first preservative-free prostaglandin tafluprost (Taflotan) in patients exhibiting ocular surface side-effects during latanoprost (Xalatan) treatment. METHODS: A total of 158 patients were enrolled in this open-label multicentre study. Eligible patients had to have at least two ocular symptoms, or one sign and one symptom, during treatment with latanoprost. At baseline, the patients were directly switched from latanoprost to preservative-free tafluprost for 12 weeks. The patients were queried for ocular symptoms, and ocular signs were assessed by using tear break-up time, Schirmer's test, fluorescein staining and evaluation of conjunctival hyperaemia and blepharitis. In addition, HLA-DR and MUC5AC in conjunctival impression cytology specimens were analyzed, and a drop discomfort/quality of life (QoL) questionnaire was employed. IOP was measured at all visits. RESULTS: Preservative-free tafluprost maintained IOP at the same level after 12- weeks treatment (16.4 +/- 2.7 mmHg) as latanoprost at baseline (16.8 +/- 2.5 mmHg). During treatment with preservative-free tafluprost, the number of patients having irritation/burning/stinging (56.3%), itching (46.8%), foreign body sensation (49.4%), tearing (55.1%) and dry eye sensation (64.6%) decreased to 28.4%, 26.5%, 27.1%, 27.1% and 39.4% correspondingly. The number of the patients with abnormal fluorescein staining of cornea (81.6%) and conjunctiva (84.2%), blepharitis (60.1%), conjunctival hyperaemia (84.2%) and abnormal Schirmer's test (71.5%) was also reduced significantly to 40.6%, 43.2%, 40.6%, 60.0% and 59.4% correspondingly. The tear break-up time improved significantly from 4.5 +/- 2.5 seconds to 7.8 +/- 4.9 seconds. A reduction in the number of patients with abnormal conjunctival cells based on HLA-DR and MUC5AC was also detected. CONCLUSIONS: Preservative-free tafluprost maintained IOP at the same level as latanoprost, but was better tolerated in patients having signs or symptoms while on preserved latanoprost. Preservative-free tafluprost treatment resulted in improved QoL, increased patient satisfaction and drop comfort.
Authors:
Hannu Uusitalo; Enping Chen; Norbert Pfeiffer; Françoise Brignole-Baudouin; Kai Kaarniranta; Markku Leino; Päivi Puska; Elina Palmgren; Thomas Hamacher; Günter Hofmann; Gernot Petzold; Ulrich Richter; Tobias Riedel; Martin Winter; Auli Ropo
Related Documents :
14564767 - Contact lenses and associated anterior segment disorders: dry eye, blepharitis, and all...
8986447 - Optic disc morphology in juvenile primary open-angle glaucoma.
6671097 - A comparative study of visual field defects seen in patients with low-tension glaucoma ...
3491447 - Pathogenesis of recurrent corneal erosion: a further aetiological factor?
23282287 - Renal replacement therapy with net fluid removal lowers intra-abdominal pressure and vo...
19196447 - The outcome of patients with unclassified hypogammaglobulinemia in early childhood.
Publication Detail:
Type:  Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Acta ophthalmologica     Volume:  88     ISSN:  1755-3768     ISO Abbreviation:  Acta Ophthalmol     Publication Date:  2010 May 
Date Detail:
Created Date:  2010-06-15     Completed Date:  2010-08-06     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101468102     Medline TA:  Acta Ophthalmol     Country:  England    
Other Details:
Languages:  eng     Pagination:  329-36     Citation Subset:  IM    
Affiliation:
University of Tampere and Tampere University Hospital, Finland. hannu.uusitalo@uta.fi <hannu.uusitalo@uta.fi>
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Topical
Adult
Aged
Aged, 80 and over
Antihypertensive Agents / administration & dosage*
Benzalkonium Compounds / administration & dosage*,  adverse effects
Blepharitis / chemically induced,  metabolism,  prevention & control
Conjunctival Diseases / chemically induced,  metabolism,  prevention & control
Exfoliation Syndrome / drug therapy*
Female
Glaucoma, Open-Angle / drug therapy*
Gonioscopy
HLA-DR Antigens / metabolism
Humans
Hyperemia / chemically induced,  metabolism,  prevention & control
Intraocular Pressure / drug effects*
Male
Middle Aged
Mucin 5AC / metabolism
Ocular Hypertension / drug therapy
Ophthalmoscopy
Patient Satisfaction
Preservatives, Pharmaceutical / administration & dosage*,  adverse effects
Prostaglandins F / administration & dosage*
Prostaglandins F, Synthetic / administration & dosage,  adverse effects
Quality of Life
Questionnaires
Tonometry, Ocular
Chemical
Reg. No./Substance:
0/Antihypertensive Agents; 0/Benzalkonium Compounds; 0/HLA-DR Antigens; 0/MUC5AC protein, human; 0/Mucin 5AC; 0/Preservatives, Pharmaceutical; 0/Prostaglandins F; 0/Prostaglandins F, Synthetic; 0/tafluprost; 130209-82-4/latanoprost

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  This issue of Acta.
Next Document:  Differences between karyotypically normal and abnormal human embryonic stem cells.